BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

Contributed by: Business Wire

Logo

Images

Business Wire embedded0

Tags

Oncology

Health

Research

Pharmaceutical

Science

Biotechnology

Name Change and Switzerland Redomiciliation

More Like This

(Graphic: Business Wire)

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

BeiGene Announces First Quarter 2025 Financial Results and Business Updates